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DObjective: Transcatheter valve-in-valve implantation is evolving as an alternative to reoperative valve replace-
ment in high-risk patients with degenerated bioprostheses. Nevertheless, hemodynamic performance is limited
by the previously implanted xenograft. We report our experience with patient–prosthesis mismatch (PPM) after
valve-in-valve implantation in the aortic position.
Methods: Eleven patients (aged 79.3  6.1 years) received transapical implantation of a balloon-expandable
pericardial heart valve into a degenerated bioprosthesis (size, 23.9  1.6 mm; range, 21–27 mm) in the aortic
position. All patients were considered high risk for surgical valve replacement (logistic European System for
Cardiac Operative Risk Evaluation, 31.8%  24.1%). Severe PPM was defined as an indexed effective orifice
area less than 0.65 cm2/m2, determined by discharge echocardiography.
Results: Severe PPM was evident in 5 patients (group 1) and absent in 6 patients (group 2). Mean transvalvular
gradients decreased from 29.2  15.4 mm Hg before implantation to 21.2  9.7 mm Hg at discharge (group 1)
and from 28.2 9.0 mm Hg before implantation to 15.2 6.5 mm Hg at discharge (group 2). Indexed effective
orifice area increased from 0.5  0.1 cm2/m2 to 0.6  0.1 cm2/m2 and from 0.6  0.3 cm2/m2 to 0.8  0.3 cm2/
m2. Aortic regurgitation decreased from grade 2.0 1.1 to 0.4 0.5 overall. No differences in New York Heart
Association class improvement or survival during follow-up were observed. One patient required reoperation for
symptomatic PPM 426 days after implantation.
Conclusions: Valve-in-valve implantation can be performed in high-risk surgical patients to avoid reoperation.
However, PPM frequently occurs, making adequate patient selection crucial. Small bioprostheses (<23 mm)
should be avoided. Implantation into 23-mm xenografts can be recommended only for patients with a body sur-
face area less than 1.8 m2. Larger prostheses seem to carry a lower risk for PPM. Although no delay in clinical
improvement was seen at short-term, 1 PPM-related surgical intervention raises concern regarding long-term
performance. (J Thorac Cardiovasc Surg 2012;143:617-24)Transcatheter valve therapies have been evolving as prom-
ising alternatives to conventional surgery in high-risk pa-
tients. Transcatheter valve-in-valve implantation can spare
elderly patients reoperative valve replacement for degener-
ated bioprostheses. First experiences with this novel ap-
proach have been published and seem appealing in the
light of the high risk associated with conventional redo sur-
gery in these frail patients.1-4 At the same time, concerns
have been raised regarding valve-in-valve function ande Departments of Cardiovascular Surgerya and General and Interventional
ology,b University Heart Center Hamburg, Germany.
ures: Dr Franzen received lecture fees from Edwards Lifesciences. All other
rs have nothing to disclose with regard to commercial support.
d L.C. contributed equally to this work.
the 91st Annual Meeting of The American Association for Thoracic Sur-
Philadelphia, Pennsylvania, May 7–11, 2011.
d for publication May 7, 2011; revisions received July 15, 2011; accepted for
cation Nov 7, 2011; available ahead of print Dec 12, 2011.
for reprints: Moritz Seiffert, MD, Department of Cardiovascular Surgery,
ersity Heart Center Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
ail: m.seiffert@uke.de).
23/$36.00
ht  2012 by The American Association for Thoracic Surgery
016/j.jtcvs.2011.11.004
The Journal of Thoracic and Cathe suitability of a variety of market-approved bioprosthe-
ses for the accommodation of 2 or 3 sizes of transcatheter
heart valves (THVs) not specifically designed for valve-
in-valve implantation. Hemodynamic performance of the
valve-in-valve construct inevitably is limited by annular ge-
ometry defined through the previously implanted xenograft
and its rigid stent.
Several cases of residual stenoses, increased transvalvu-
lar gradients, and low effective orifice areas (EOAs) have
been described after valve-in-valve procedures,5 making
patient–prosthesis mismatch (PPM) a concern.6 PPM has
been extensively investigated as a potential problem after
surgical valve replacement and is considered as an EOA
of the valve prosthesis that is physiologically too small in
relation to the patient’s body surface area (BSA).7 The ratio-
nale is that a smaller EOAwill result in higher transvalvular
gradients. The indexed EOA (iEOA) is the only parameter
found to consistently correlate with postoperative gradients.
PPM is generally defined as iEOA 0.85 cm2/m2 or less
(moderate) or iEOA 0.65 cm2/m2 or less (severe).8 Al-
though there has been much controversy regarding the influ-
ence of moderate PPM, there has been considerablerdiovascular Surgery c Volume 143, Number 3 617
Abbreviations and Acronyms
AR ¼ aortic regurgitation
AVR ¼ aortic valve replacement
BSA ¼ body surface area
EOA ¼ effective orifice area
iEOA ¼ indexed effective orifice area
NYHA ¼ New York Heart Association
PPM ¼ patient–prosthesis mismatch
THV ¼ transcatheter heart valve
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Devidence that severe PPM has a negative impact on patient
outcome.9
By implanting 1 valvewithin another instead of replacing
it and the lack of oversizing, valve-in-valve procedures
seem predestined for the occurrence of PPM. This problem
has been investigated in vitro. Although implantation of
a 23-mm THV into a stented 23-mm bioprosthesis reduced
transprosthetic pressure gradients and improved EOA
similar to surgical aortic valve replacement (AVR), implan-
tation into smaller valves insufficiently relieved the steno-
sis.10 Furthermore, the rigidity of the bioprosthesis stent
can constrain oversized valve-in-valve implantation and
prevent full expansion, leading to leaflet distortion and sub-
sequent transvalvular aortic regurgitation (AR).
Systematic investigation of PPM after valve-in-valve im-
plantation has not been performed. The current study retro-
spectively analyzed the data of valve-in-valve implantations
performed at University Heart Center Hamburg to address
this issue and attempts to offer guidance to prevent this po-
tential problem.MATERIALS AND METHODS
Patient Population
FromAugust 2008 toMarch 2011, 11 patients were admitted to the Uni-
versity Heart Center Hamburg with significant signs of valve dysfunction
(stenosis, regurgitation, mixed disease) long-term after bioprosthetic
AVR. Indication for valve replacement was based on current guidelines.11
All patients presented with severe comorbidities precluding them from sur-
gical treatment as determined by an interdisciplinary heart team. Preoper-
ative transesophageal echocardiography was used to determine valve
pathology and inner stent diameter; computed tomography scans of the aor-
tic arch and femoral vessels were used to assess vascular status. The trans-
apical approach was chosen for the straight and short access to the site of
valve implantation in all patients.
Transcatheter Valve-in-Valve Implantation
Transcatheter valve-in-valve implantation was performed in a specially
equipped hybrid suite under general anesthesia, as previously described.3
Briefly, after left lateral minithoracotomy and ventricular pacemaker-lead
placement, pursestring sutures were applied and a transapical guidewire
was inserted. Subsequently, the crimped Edwards SAPIEN THV (Edwards
Lifesciences LLC, Irving, Calif) was introduced through a sheath and de-
ployed into the degenerated xenograft prosthesis antegrade in the aortic po-
sition without prior balloon valvuloplasty of the degenerated prosthesis.618 The Journal of Thoracic and Cardiovascular SurgThese steps were carried out under rapid ventricular pacing and fluoro-
scopic control. Subsequently, valve performance was assessed by transeso-
phageal echocardiography and fluoroscopy. A 23-mm balloon-expandable
valve was used in 10 patients, and a 26-mm device was used in 1 patient.
Echocardiographic Assessment and Follow-up
Transthoracic echocardiography was performed at baseline and before
discharge.12 The EOA was assessed using the continuity equation ap-
proach. The iEOA was calculated by dividing the EOA with the patient’s
BSA, computed using the Dubois formula (BSA [m2]¼ 0.007184 $weight
[kg]0.425 $ height [cm]0.725). According to the literature, severe PPM was
defined as iEOA 0.65 cm2/m2 or less.8 Patients with severe PPM after
valve-in-valve implantation were included in group 1. Patients without
echocardiographic evidence of severe mismatch were included in group
2. Follow-up was performed at 30 days, 6 months, and 1 year, if applicable,
collecting data regarding functional status (New York Heart Association
[NYHA] class), echocardiographic valve function, and mortality.
Statistical Methods
Continuous variables are expressed as mean  standard deviation, and
categoric variables are expressed as proportions (%). The mean values of
continuous variables were compared using the Student t test generating
2-tailedP values. Categoric variables were compared using the Fisher exact
test. Cumulative probability of survival was estimated using the Kaplan–
Meier method and compared between groups using the log-rank test. All
statistical analyses were performed using GraphPad Prism version 5.02
(GraphPad Software, Inc, La Jolla, Calif).
RESULTS
The study population was predominantly male with
a mean age of 79.1  6.3 years (range, 70–88 years;
Table 1). Patients were admitted with severe degeneration
of the implanted bioprostheses 12.6  6.2 years after surgi-
cal AVR. Ten patients had stented bioprostheses sizes 21 to
25 mm in situ, and 1 patient had a stentless 27-mm valve
(Table 2). Overall, 4 patients (36%) primarily displayed
signs of stenosis of the previously implanted xenograft,
and 4 patients (36%) presented with regurgitation, mostly
due to prolapse of a single cusp. Three patients (27%)
showed a mixed disease. Baseline characteristics including
echocardiographic measurements and comorbidities are
presented in Table 1. After transcatheter aortic valve-in-
valve implantation, 5 patients had an iEOA 0.65 cm2/m2
or less (severe PPM, group 1), 5 patients had an iEOA
less than 0.85 cm2/m2 but greater than 0.65 cm2/m2 (moder-
ate PPM, group 2), and 1 patient had an iEOA greater than
0.85 cm2/m2 (no PPM, group 2), as determined by echocar-
diography at discharge. No statistically significant differ-
ences in baseline parameters were observed between both
groups, although there was a trend toward a higher risk pro-
file in group 1.
In both groups, the iEOA improved only slightly after
valve-in-valve implantation, missing statistical significance
(group 1, 0.50  0.13 to 0.58 0.06 cm2/m2; group 2, 0.62
 0.27 to 0.83  0.28 cm2/m2; Figure 1, A). A significant
reduction in mean aortic valve gradient from 28.2  9.0
mm Hg at baseline to 15.2  6.5 mm Hg at discharge was
observed in group 2 (P¼ .02), whereas only a mild decreaseery c March 2012
TABLE 1. Baseline and clinical parameters, mean ± standard deviation
Group 1 (iEOA  0.65 cm2/m2) Group 2 (iEOA>0.65 cm2/m2) P value
n 5 6
Age (y) 75.5  5.6 82.2  5.4 .07
Sex (male) 5/5 (100%) 4/6 (67%) .45
BMI (kg/m2) 26.7  5.5 23.3  2.2 .20
BSA (m2) 2.0  0.3 1.8  0.2 .22
Preoperative diagnosis
AS 2/5 (40%) 2/6 (33%) 1.0
AR 1/5 (20%) 3/6 (50%) .54
Mixed disease 2/5 (40%) 1/6 (17%) .39
Preoperative AVG mean (mm Hg) 29.2  15.4 28.2  9.0 .90
Preoperative iEOA (cm2/m2) 0.5  0.1 0.6  0.3 .39
Preoperative AR (grade) 2.0  1.1 2.0  1.3 1.0
Interval to index procedure (y) 12.4  8.0 12.8  5.1 .92
Size bioprosthesis (mm) 23.8  2.3 24.0  1.1 .85
Inner stent diameter (mm) 21.0  1.9 20.2  1.1 .40
Size implanted THV (mm) 23.6  1.3 23.0  0.0
Coronary artery disease 2/5 (40%) 3/6 (50%) 1.0
Previous CABG 1/5 (20%) 2/6 (33%) 1.0
Extracardiac arteriopathy 3/5 (60%) 1/6 (17%) .24
Preoperative creatinine (mg/dL) 2.4  2.5 (range, 0.6–8.9) 1.1  0.3 (range, 0.6–1.4) .23
Severe pulmonary disease 4/5 (80%) 2/6 (33%) .24
Malignant disease 1/5 (20%) 0/6 (0%) .45
Preoperative LVEF (%) 47.0  23.1 52.5  10.4 .61
Preoperative NYHA class 3.2  0.4 3.0  0.7 .60
Logistic euroSCORE (%) 42.0  32.9 23.3  10.0 .21
STS PROM (%) 17.8  14.6 8.0  7.0 .18
Statistical analysis was performed using the Student t test for continuous and Fisher exact test for categoric variables. Inner stent diameter was measured by transesophageal
echocardiography. iEOA, Indexed effective orifice area; BMI, body mass index; BSA, body surface area; AS, aortic stenosis; AR, aortic regurgitation; AVG, aortic valve gradient;
THV, transcatheter heart valve; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; euroSCORE, European
System for Cardiac Operative Risk Evaluation; STS PROM, Society of Thoracic Surgeons Predicted Risk of Mortality.
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Dfrom 29.2 15.4 mmHg at baseline to 21.2 9.7 mmHg at
discharge was detected in group 1 (P ¼ not significant). At
later follow-up visits, no significant differences were found
in either group compared with baseline (Figure 1, B).
AR was reduced from grade 2.0  1.3 to 0.3  0.5
(P ¼ .04) in group 2 and from grade 2.0  1.1 at baseline
to 0.4  0.5 at discharge in group 1 (P ¼ .06). After valve-
in-valve implantation, AR was trace in all but 1 patient
who had a grade 2 paravalvular AR at 6-month follow-upTABLE 2. Parameters of implanted bioprostheses and transcatheter heart
Patient no. Bioprosthesis size
1 21 mm Medtronic Hanc
2 23 mm Carpentier Edw
3 23 mm Medtronic Hanc
4 23 mm Medtronic Hanc
5 23 mm Medtronic Hanc
6 23 mm St Jude Biocor (
7 25 mm Medtronic Hanc
8 25 mm Medtronic Hanc
9 25 mm Medtronic Mosa
10 25 mm St Jude Biocor
11 27 mm Medtronic Frees
THV, Transcatheter heart valve.
The Journal of Thoracic and Cathat was not considered to be clinically relevant at this point
(Figure 1,C). No significant changes in left ventricular ejec-
tion fraction were noted in either group (Figure 1, D).
NYHA class improved from 3.2  0.4 before the proce-
dure to 1.7  0.5 at 30-day follow-up in group 1 (P ¼ .01)
and from 3.0  0.71 to 2.2  0.45 in group 2 (P ¼ .03). At
6-month follow-up, no significant improvement was seen
from baseline in either group (group 1, NYHA class 2.5
 1.3; group 2, NYHA class 2.0  0.8; Figure 2, A).valves
Bioprosthesis type THV size4
ock (Medtronic Inc, Minneapolis, Minn) 23 mm
ards (Edwards Lifesciences LLC, Irvine, Calif) 23 mm
ock 23 mm
ock 23 mm
ock 23 mm
St Jude Medical, St Paul, Minn) 23 mm
ock 23 mm
ock 23 mm
ic (Medtronic Inc) 23 mm
23 mm
tyle (Medtronic Inc) 26 mm
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FIGURE 1. A, iEOA before and after transcatheter valve-in-valve implantation did not improve significantly in either group. B, Mean AVG decreased
significantly after valve-in-valve implantation only in patients without severe PPM, but this effect was lost over a 6-month follow-up. Reduction in AR after
implantation was significant only for patients in group 2. C, At 6-month follow-up, no significant effect was detectable. D, No changes in left ventricular
ejection fraction were observed during follow-up in either group. Mean  standard deviation. Statistical analysis was performed using the paired Student t
test. AVG, Aortic valve gradient; iEOA, indexed effective orifice area; AR, aortic regurgitation; FU, follow-up; LVEF, left ventricular ejection fraction.
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DIn group 1, 1 patient died of low cardiac output on day 8
and 1 patient died of ametastasizing prostate carcinoma 246
days after the procedure. One patient required surgical AVR
and root remodeling for symptomatic stenosis (iEOA, 0.4FIGURE 2. A, NYHAclass improved significantly at 30-day follow-up in both
follow-up. Cumulative survival was estimated using the Kaplan–Meier method.
(P ¼ .67). B, One patient required surgical AVR 426 days after implantation an
Association.
620 The Journal of Thoracic and Cardiovascular Surgcm2/m2) 426 days after valve-in-valve implantation into
a 21-mm bioprosthesis. He was in good clinical condition
at the latest follow-up. In group 2, 1 patient died of sudden
cardiac failure at the rehabilitation clinic on day 33. Bystudy groups, but no statistically significant differencewas noted at 6-month
Log-rank test did not detect any differences in survival between both groups
d was censored alive at that date. FU, Follow-up; NYHA, New York Heart
ery c March 2012
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ferences in survival between both groups were observed
(P ¼ .67; Figure 2, B).
DISCUSSION
Valve-in-valve implantation can be performed to avoid re-
operative valve replacement in frail and elderly patients who
are no candidates for conventional surgery. The small num-
ber of patients constitutes amajor limitation of the presented
study. Several groups have published encouraging outcomes
after valve-in-valve procedures.1,4 The results were rather
satisfactory in our experience. This corresponds to the
fact that approximately half of the study patients had
signs of severe PPM, as measured by postoperative
echocardiography. All but 1 patient had at least moderate
PPM (Figure 3, A and B). To analyze an effect of PPM on
postoperative outcome, we focused on patients with severe
PPM and compared them with the remainder of patients.
In line with the literature on this topic, improvement in
valve function in patients with severe PPM was ambivalent:
Transvalvular gradients were significantly reduced only in
patients without severe PPM underlining the correlation
of iEOA and aortic valve gradient (Figure 3, A). The signif-
icance to this effect was lost over follow-up, probably be-
cause of the small number of patients. Because at least
moderate PPM was present in the majority of patients, no
significant increase in iEOA was observed in either group.
Subsequently, a persistent relative aortic stenosis might pre-
clude an adequate left ventricular afterload relief in patients
with severe PPM impeding left ventricular mass regression.
Echocardiographic measurements of wall thickness and
ventricular dimensions were not concise enough in this
study to relate changes in left ventricular volume and hyper-
trophy to PPM. Nevertheless, in our experience, implanta-
tion of a THV into a 21-mm bioprosthesis did not
sufficiently relieve stenosis, resulting in reoperation in
that patient. Consequently, we prefer to avoid the describedFIGURE 3. A, Relationship of meanAVG and iEOA at discharge. B, Relation of
and BSA of 2.4 m2 had severe PPM despite valve-in-valve implantation into a 27
bioprostheses:-, 21 mm;C, 23 mm;A, 25 mm;:, 27 mm. AVG, Aortic valv
The Journal of Thoracic and Caprocedure in patients with previously implanted bioprosthe-
ses less than 23 mm. In our experience, implantation of
a THV into 23-mm xenografts can be recommended only
for patients with a BSA less than 1.8 m2 to achieve a suffi-
cient iEOA, relieve stenosis, and avoid severe PPM. Larger
prostheses seem to carry a lower risk for PPM unless BSA
increases to the same extent (Figure 3, A and B). This is in
linewith invitro data published byAzadani and coworkers10
and our own experience.3 We found that implantation of
a 23-mmTHVinto a 25-mm xenograft achieves a geometric
EOA of 2.4 cm2, whereas implantation into a 21-mm stented
bioprosthesis offers only 1.4 cm2 at maximum (Figure 4). Of
note, the geometric EOA significantly overestimates the ac-
tual in vivo EOA.
A clinically relevant reduction of AR was achieved in all
patients. Valve-in-valve implantation may therefore be su-
perior in the treatment of regurgitation rather than stenosis
due to bioprosthetic degeneration. Because only 2 patients
had trace paravalvular and 2 other patients displayed trace
transvalvular AR after valve-in-valve implantation, relevant
constraint of the THV due to the rigid bioprosthesis stent
and subsequent leaflet distortion seem to be minor prob-
lems. Nevertheless, the fact that 1 patient had an increasing
paravalvular AR (grade 2 at 6-month follow-up) empha-
sizes that alignment of bioprosthesis and THV can be hin-
dered by uneven stent expansion and calcifications
distorting the circular geometry. Development of specific
THV containing a cuff for optimal alignment and reduction
of paravalvular AR is under way and might solve this prob-
lem. However, cuffed THV might carry a wider stent that
further decreases the resulting EOA.
Both study groups showed a mildly reduced mean left
ventricular ejection fraction at baseline. No significant im-
provement was observed during follow-up in either group,
perhaps because of persistent relative stenosis and a short
follow-up time. From a clinical perspective, NYHA class
improvement was seen within early follow-up in patientsiEOA andBSA at discharge. One patient with bodymass index of 34.0 kg/m2
-mm stentless prosthesis. Area of PPM (grey). Sizes of previously implanted
e gradient; iEOA, indexed effective orifice area; BSA, body surface area.
rdiovascular Surgery c Volume 143, Number 3 621
FIGURE 4. Transcatheter valve-in-valve implantation of a 23-mm Edwards SAPIEN (Edwards Lifesciences LLC, Irving, Calif) valve into a 23-mm bio-
prosthesis (A) and 21-mm stented bioprosthesis (B, C). Uneven stent expansion (arrows). Implantation into a 25-mm stented bioprosthesis confirms superior
stent expansion and alignment within the larger bioprosthesis (D–F). Positioning of the THVwith the lower third overlapping the sewing ring of the surgical
prosthesis for optimal anchoring, valve expansion, and reduction of atrioventricular conduction disturbances (A, D). B, C, E, and F are modified with per-
mission from John Wiley & Sons, Inc.3
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profound symptoms of heart failure in conjunction with se-
vere PPM. He required surgical reoperation including aortic
root enlargement more than 1 year after implantation, em-
phasizing the potential problems adherent with PPM.
With regard to survival, no differences were seen between
the 2 groups.
Much effort has been made to investigate the nature of
PPM in patients receiving surgical AVR. Approximately
2% to 11% of these patients have severe PPM, and 20%
to 70% have moderate PPM.9 After TAVI, an incidence
of severe PPM of up to 16% has been reported.13 Although
the influence of PPM on short- and long-term survivals is
still controversial, in part because of methodical discrep-
ancies, there is considerable evidence that severe PPM
has a detrimental effect on patient outcome.8,13-19 In
contrast with most other cardiovascular risk factors, PPM
can largely be prevented and should therefore be avoided.
For TAVI and valve-in-valve procedures, where additional
surgical procedures (eg, aortic root enlargement) are not
available, it is crucial to carefully select the patients and
THV type and size. A major concern is the size and type
of the previously implanted bioprosthesis. This issue might
become secondary once smaller THV sizes and specific622 The Journal of Thoracic and Cardiovascular Surgvalve-in-valve THV become available. Another interesting
approach is the supravalvular implantation of a specifically
designed THV into the xenograft, potentially offering
a larger EOA.20
An important aspect that has to be addressed in a larger-
scale study is the question of which bioprostheses are espe-
cially capable of accommodating a THV with sufficient
alignment of the valve-in-valve construct offering adequate
valve function. Furthermore, hemodynamic properties of
different THV types in valve-in-valve position should be
compared. The balloon-expandable Edwards SAPIEN
valve with its low frame height and precise placement
seems to be an ideal candidate for valve-in-valve implanta-
tion. However, the long frame design of the CoreValve de-
vice (Medtronic Inc, Minneapolis, Minn) may allow
a supra-annular placement of the prosthesis, resulting in
an increased EOA and superior hemodynamic function, es-
pecially in small bioprostheses.
CONCLUSIONS
PPM frequently occurs and has to be considered when
planning valve-in-valve procedures. In this study, no delay
in clinical improvement was seen in patients with severe
PPM at short-term. Apart from short follow-up duration,ery c March 2012
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Dthis might also be attributed to a lack of physical exertion
and maximum cardiovascular effort to detect differences
in these elderly and frail patients. Objective functional mea-
surements of cardiovascular capacity may have offered
deeper insights. However, 1 PPM-related surgical interven-
tion raises concerns about a potential problem that needs to
be considered when planning a valve-in-valve implantation.
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DrMathewWilliams (New York, NY). This study has a limited
number of patients, so it is hard to make any overwhelming con-
clusions. However, rather than dwell on that, I commend you and
the American Association for Thoracic Surgery for deciding to
address this issue while this technology is in its infancy. I and
several of my colleagues have already changed our surgical strat-
egy in younger patients. We are using tissue valves in much
younger patients with almost a planned bailout strategy in the fu-
ture of performing a transcatheter valve-in-valve rather than
a reoperation.
I have 1 comment about the data. I find it is somewhat difficult
to try to evaluate the data in terms of looking at EOA, AR grades,
andmean gradient as an average for thewhole population when the
reality is that approximately one third had pure aortic stenosis, one
third had pure aortic insufficiency, and one third had mixed. This
leads me to my first question. I realize it is entirely anecdotal, but
can you comment on any clinical differences, functional differ-
ences, in the patients who presented with more aortic stenosis or
more insufficiency? It might make sense that in a patient who
has severe aortic stenosis it would be worth doing this procedure
even if you are going to have some PPM, but perhaps our bar
should be a little higher for those with aortic insufficiency.
Dr Seiffert. As you stressed, the limited number of patients in
the presented study makes it difficult to distinguish any clinical or
functional differences as symptoms or left ventricle dimensions.
What I would draw from our data is that the patients may have
profitedmore from a significant reduction of AR rather than a com-
plete relief of stenosis. Therefore, I would imagine that patients
with AR due to bioprosthetic degeneration would profit the most
from this procedure.
Dr Williams. It would be interesting at some point to see what
their left ventricle dimensions were, but, again, it is a small num-
ber. Can you provide some guidance given that a lot of us are put-
ting tissue valves in younger patients now? Is there an absolute size
that we need to put in patients in whom we are going to try this ap-
proach? Perhaps we need to pick their ideal size and add +1 to that,
even if it means doing a root enlargement more aggressively in
these patients.
Dr Seiffert. We have been discussing this topic thoroughly in
our department. As you already stated, patient age is important
to that matter. If patients receive a bioprosthesis now, and thererdiovascular Surgery c Volume 143, Number 3 623
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Dis a chance they will require a valve replacement because of degen-
eration in 10 or 15 years, we should plan ahead. Because of the po-
tential problem of PPM, we would rather implant a larger
bioprosthesis, even if a root enlargement has to be done to accom-
modate at least a 23-mm valve. Current studies suggest that root
enlargement is not associated with an increase in morbidity and
mortality due to the surgical procedure.
We should still keep in mind, as emphasized by Dr Moon in his
lecture on PPM, that we do not necessarily see a clinical result or
a corollary to the PPM, as determined by echocardiography. Some
of these patients may not reach the level of physical activity nec-
essary to experience symptoms or functional changes (eg, in terms
of left ventricular mass) due to a persistent stenosis in the light of
PPM.
Dr Lucian Lozonschi (Madison, Wis). I congratulate you for an
interesting and timely article. It is inevitable now not to tell pa-
tients, especially for the past year or so, about the option of
valve-in-valve implantation in the future.
I have 2 questions, 1 related to your incidence of paravalvular
leak, which we all think should be zero or very small. I haven’t
seen you report that in the results presented. Were you aware of
any rumors of a smaller valve size that can address that issue, or
for now shall we stick with putting in larger valves (>23)?
Dr Seiffert. I agree that paravalvular regurgitation is not a sig-
nificant problem after valve-in-valve procedures. Apart from 1 pa-
tient with a grade 2 paravalvular regurgitation, the remaining
patients had no or trivial AR. We follow these patients closely
and have not seen any changes in regurgitation or influence on
outcome.
To my knowledge, developments of a cuffed transcatheter
valve-in-valve prosthesis are under way to avoid any paravalvular
leakage. I would imagine this might also reduce the EOA and may
therefore not be beneficial with regard to PPM. I do not have any
information on smaller THVs being developed for implantation
into smaller bioprostheses.
Dr Bansi Koul (Lund, Sweden). Given the small number of pa-
tients, did you have an opportunity to see if these patients who had
the valves preoperatively, and based on the EOA of those valves
already, had some sort of PPM and this is where it became exag-
gerated in the group?624 The Journal of Thoracic and Cardiovascular SurgDr Seiffert. Are you referring to data before valve-in-valve im-
plantation as opposed to afterward?
Dr Koul. Yes. Do you have some data based on the valves they
had in the first instance and from their given BSA that they already
had some degree of PPM that became exaggerated after you did
a valve-in-valve procedure?
Dr Seiffert. The iEOA did not really significantly change after
valve-in-valve implantation. It would have been interesting to ret-
rospectively look at potential PPM immediately after the index
procedure 12.5 years ago, for example, echocardiography mea-
surements from back then. Unfortunately, we do not have these
data. Because EOA calculations based on the geometric EOA pro-
vided by the manufacturer overestimate the actual opening area,
we did not perform these calculations.
Dr Christopher Young (London, UK). We have done more
than 15 valve-in-valve procedures, and we haven’t seen anything
like this in our population. We wouldn’t expect to see gradients
or AR, and yet you showed some deformity when you are actually
putting this device into somebody who has a strong circular annu-
lus. Can you explain why you are seeing problems with regurgita-
tion and the deformity, because I wouldn’t actually expect that?
How bad are the symptoms in these patients who have a mis-
match, how much of it is echocardiographic data, and how much
of it is symptomatic if this procedure is done for symptoms in el-
derly patients?
Dr Seiffert. One patient presented with strong symptoms after
valve-in-valve implantation, NYHA class IV, received reoperative
valve replacement combined with root enlargement, and has been
doing well since then. In the remaining 10 patients, it is difficult to
differentiate the symptoms, because these are elderly patients with
significant comorbidities, such as pulmonary disease. I agree that
a symptom-based approach is appropriate in these elderly patients.
Nevertheless, PPM is a potential problem that has to be considered
when planning valve-in-valve procedures.
In regard to your first question, we agree that paravalvular AR is
not an issue in valve-in-valve procedures. By referring to the
pictures from bench ex vivo valve-in-valve implantations, you cer-
tainly note an uneven stent expansion after implantation of
a 23-mm THV into a 21-mm rigid stent that may result in leaflet
distortion and subsequent transvalvular regurgitation.ery c March 2012
